Recently, strategies have shifted to early prevention and delaying OA progression before major damage.[5c] Low‐grade chronic inflammation in the joint can promote OA progression, such as TNF‐α, IL‐1, IL‐6, and IL‐8, which were shown to trigger joint inflammation, which leads to cartilage degeneration.[5, 8] Traditional anti‐inflammatory drugs, such as COX inhibitors (e.g., celecoxib), are commonly used to alleviate pain and inflammation in OA patients. The gene discussed is TNF; the disease is inflammatory response.